Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 27.9% during mid-day trading on Friday . The stock traded as high as C$0.29 and last traded at C$0.28. Approximately 1,401,717 shares traded hands during trading, an increase of 100% from the average daily volume of 700,531 shares. The stock had previously closed at C$0.22.
Hemostemix Price Performance
The firm has a market cap of C$23.96 million, a PE ratio of -13.75 and a beta of 0.20. The stock has a 50-day moving average price of C$0.10 and a 200 day moving average price of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What is the Nasdaq? Complete Overview with History
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
- Earnings Per Share Calculator: How to Calculate EPS
- Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
